ClinicalTrials.gg
Enrolling by invitationNCT06558201Updated Aug 17, 2026

Open Label Extension Study of NCT06221852

An interventional study of Ketogenic diet in Bipolar I Disorder, Schizoaffective Disorder and Psychosis, sponsored by Mclean Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Mclean Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Psychotic Disorders by Mclean Hospital — 6 open to participants now, 6 under way, none of them phase 3. Psychotic Disorders · Mclean Hospital.

Planned enrollment
8th of 17
50 · median 50
Started
2024
with 3 others
No phase
11 of 18
6 open now
Registered
17th of 18
by date

Among the 18 studies in Psychotic Disorders by Mclean Hospital, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 4 that started in 2024, is one of 11 with no phase, and was the 17th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

6 of the 18 studies in Psychotic Disorders by Mclean Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Psychotic Disorders by Mclean Hospital, or all of them as a file.
02

Study summary

This is a 12-week open-label extension study for participants completing study NCT06221852.

Read the detailed description

In this 12-week single arm open label extension study of NCT06221852, the investigators aim to assess the longer term efficacy, safety and tolerability of the ketogenic diet in participants completing the randomized study phase of NCT06221852. Investigators will assess longer term effects on energy metabolism, insulin resistance and psychiatric symptoms.

03

Conditions studied

  • Bipolar I Disorder
  • Schizoaffective Disorder
  • Psychosis

Keywords

  • First episode psychosis
  • Ketogenic diet
  • Keto
  • Brain energy metabolism
  • Insulin resistance
  • Schizoaffective disorder
  • Bipolar disorder
  • Magnetic resonance spectroscopy (MRS)
  • Redox
  • Creatine kinase
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who met original entry criteria in, and completed, the randomized 12-week study of NCT06221852.

Exclusion criteria

Exclusion Criteria:

-No longer meeting original entry criteria from the randomized 12-week study of NCT06221852.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Ketogenic diet

    Participants will be asked to follow the ketogenic diet (KD) for 12 weeks in addition to any ongoing medications (e.g., mood stabilizers and/or second-generation antipsychotics). Participants will receive diet counseling from a registered dietitian. Participants will be asked to monitor and report their blood ketone and glucose levels each day via a finger-prick device provided by the study team.

    Other: Ketogenic diet

Interventions

  • OtherKetogenic diet

    The ketogenic diet (KD) is a normo-caloric diet composed of high-fat, low carbohydrate, and adequate protein intake. The KD will consist of 3 meals a day plus snacks, targeting 75-80% fat, 13-18% protein, 7% carbohydrates.

    Also known as: Keto diet

06

What researchers measure

Primary outcomes

  1. Change in brain redox nicotinamide adenine dinucleotide metabolites ratio (NAD+/NADH)

    Change from baseline to week 24 in NAD+/NADH as measured by in vivo phosphorus magnetic resonance spectroscopy (31P-MRS).

    Time frame: 24 weeks

  2. Change in brain creatine kinase forward reaction rate (kf)

    Change from baseline to week 24 in creatine kinase forward reaction rate (kf) as measured by 31P magnetization transfer (MT) MRS.

    Time frame: 24 weeks

  3. Change in insulin resistance

    Change from baseline to week 24 of insulin resistance measured using the homeostatic model assessment of insulin resistance (HOMA-IR) using fasting blood glucose and insulin levels.

    Time frame: 24 weeks

  4. Change in psychotic symptoms

    Change from baseline to week 24 in Positive and Negative Syndrome Scale (PANSS) total score. Scores range from 30-210; a higher score indicates a higher level of psychotic symptoms.

    Time frame: 24 weeks

  5. Change in depressive symptoms

    Change from baseline to week 24 in Hamilton Rating Scale for Depression (HAM-D) total score. Scores range from 0-52; a higher score indicates a higher level of depression.

    Time frame: 24 weeks

  6. Change in mania symptoms

    Change from baseline to week 24 in Young Mania Rating Scale (YMRS) total score. Scores range from 0-60. A higher score indicates a more severe illness.

    Time frame: 24 weeks

  7. Change in Clinical Global Impression (CGI) Scale

    Change from baseline to week 24 in Clinical Global Impression (CGI) Scale. Scores range from 1-7; a higher score indicates higher severity of illness.

    Time frame: 24 weeks

Secondary outcomes

  1. Change in body weight

    Change from baseline to week 24 in participant body weight in kilograms, as measured using a standing scale.

    Time frame: 24 weeks

  2. Change in glycated hemoglobin (Hemoglobin A1c) level

    Change from baseline to week 24 in fasting Hemoglobin A1c level.

    Time frame: 24 weeks

  3. Change in triglyceride levels

    Change from baseline to week 24 in fasting triglyceride levels.

    Time frame: 24 weeks

  4. Change in low-density lipoprotein (LDL) levels

    Change from baseline to week 24 in fasting LDL levels

    Time frame: 24 weeks

  5. Change in high-density lipoprotein (HDL) levels

    Change from baseline to week 24 in fasting HDL levels

    Time frame: 24 weeks

  6. Change in high-sensitivity C-reactive protein (hs-CRP) levels

    Change from baseline to week 24 in fasting hs-CRP levels.

    Time frame: 24 weeks

  7. Change in brain gamma-aminobutyric acid (GABA) concentration

    Change from baseline to week 24 in GABA concentration measured by proton magnetic resonance spectroscopy.

    Time frame: 24 weeks

  8. Change in brain glutamate metabolite concentration

    Change from baseline to week 24 in glutamate metabolite concentration measured by proton magnetic resonance spectroscopy.

    Time frame: 24 weeks

  9. Change in brain glutathione (GSH)

    Change from baseline to week 24 in brain GSH measured by proton magnetic resonance spectroscopy.

    Time frame: 24 weeks

  10. Change in brain Phosphocreatine (PCr)

    Changes from baseline to week 24 in PCr concentration as measured by in vivo 31P-MRS.

    Time frame: 24 weeks

  11. Change in brain pH

    Change from baseline to week 24 in pH as measured by in vivo 31P MRS

    Time frame: 24 weeks

  12. Change in brain inorganic phosphate concentration

    Change from baseline to week 24 in inorganic phosphate (Pi) concentration as measured by in vivo 31P MRS.

    Time frame: 24 weeks

  13. Change in adverse events

    Change from baseline to week 24 in adverse events.

    Time frame: 24 weeks

  14. Change in anxiety symptoms

    Change from baseline to week 24 from baseline to week 12 in Hamilton Anxiety Rating Scale (HAM-A) total score. Scores range from 0 - 56; a higher score indicates a higher level of anxiety.

    Time frame: 24 weeks

  15. Change in stress symptoms

    Change from baseline to week 24 in Depression Anxiety Stress Scales (DASS-42) Stress Subscale score. Scores range from 0-42; a higher score indicates a higher level of stress.

    Time frame: 24 weeks

  16. Change in cognitive performance

    Change from baseline to week 24 in Matrics Consensus Cognitive Battery (MCCB) Total Score. Scores range from 0.00% - 100.00%; a higher score indicates higher cognition.

    Time frame: 24 weeks

  17. Change in Global Functioning Scale (GFS) - Social and Role total score

    Change from baseline to week 24 in Global Functioning Scale (GFS) - Social and Role total score. Scores range from 6-60; a lower score indicates worse social and role functioning.

    Time frame: 24 weeks

  18. Change in blood NAD/NADH+ ratio

    Change from baseline to week 24 in blood NAD/NADH+ ratio.

    Time frame: 24 weeks

  19. Change in blood GSH/GSSH ratio

    Change from baseline to week 24 in blood GSH/GSSH ratio.

    Time frame: 24 weeks

  20. Change in growth differentiation factor 15 (GDF15)

    Change from baseline to week 24 in blood and saliva GDF15 levels.

    Time frame: 24 weeks

  21. Change in cell-free mitochondrial DNA (cf-mtDNA)

    Change from baseline to week 24 in blood and saliva cf-mtDNA levels.

    Time frame: 24 weeks

Other outcomes

  1. Change in World Health Organization Disability Assessment Schedule (WHODAS) score

    Change from baseline to week 24 in World Health Organization Disability Assessment Schedule (WHODAS) scale. Scores range from 0-144. A higher score indicates greater dysfunction and disability in major life domains.

    Time frame: 24 weeks

  2. Change in World Health Organization Quality of Life (WHOQOL) score

    Change from baseline to week 24 in World Health Organization Quality of Life (WHOQOL) scale. Scores range from 1-130. A lower score indicates lower perceived quality of life.

    Time frame: 24 weeks

  3. Change in Extrapyramidal Symptom Rating Scale (ESRS) total score

    Change from baseline to week 24 in Extrapyramidal Symptom Rating Scale (ESRS) total score. Scores range from 0-102; a higher score indicates more severe symptoms.

    Time frame: 24 weeks

  4. Change in Pittsburgh Sleep Quality Index (PSQI) total score

    Change from baseline to week 24 in Pittsburgh Sleep Quality Index (PSQI) total score. Scores range from 0-21; a higher score indicates worse sleep quality.

    Time frame: 24 weeks

  5. Change in resting-state fMRI

    Change within network positive correlations and between network negative correlations from baseline to week 24.

    Time frame: 24 weeks

  6. Change in gray matter volume

    Change in the gray matter volumes (cubic millimeters) of the frontal, parietal and temporal lobes as defined by Freesurfer's Desikan-Killiany Brain Atlas from baseline to week 24.

    Time frame: 24 weeks

  7. Change in cortical surface area

    Change in the cortical surface area (millimeters squared) of the frontal, parietal and temporal lobes as defined by Freesurfer's Desikan-Killiany Brain Atlas from baseline to week 24.

    Time frame: 24 weeks

  8. Change in white matter fractional anisotropy (FA)

    Change in fractional anisotropy (FA), a scalar measure of diffusivity, of water in the brain assessed by DTI at 3T from baseline to week 24. FA values range from 0 (isotropic, meaning diffusion is equally restricted in 3D space) to 1 (anisotrophic, meaning that diffusion is completely restricted to a single direction).

    Time frame: 24 weeks

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Sep 2027, 37 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 37 months is close to that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2024
First posted
Aug 16, 2024
StartActual
Aug 28, 2024
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06558201
Lead sponsor
Mclean Hospital
Collaborators
Baszucki Family Foundation
Responsible party
Virginie-Anne Chouinard, MD (Principal Investigator, Mclean Hospital) — Principal investigator
First posted
Aug 16, 2024
Start date
Aug 28, 2024
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

Virginie-Anne Chouinard, MD
principal investigator · Mclean Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion